Improving Our Early Warning System for AML
A more sensitive approach to monitoring acute myeloid leukemia relapse after bone marrow transplant
Amanda Winters | | Longer Read
At a Glance
- Bone marrow transplants can be a curative therapy for acute myeloid leukemia, but a significant proportion of patients still relapse
- Chimerism testing is routinely used to monitor relapse in transplanted patients, but a more sensitive, effective method is needed
- Droplet digital PCR measures the concentration of bone marrow-derived DNAs containing AML-associated mutations to offer a reliable approach to relapse monitoring
- The technique enables physicians to detect signs of relapse sooner, giving them more time to plan treatment regimens for their patients
Acute myeloid leukemia (AML) can be a devastating disease – but it’s not without treatment options; for example, allogeneic bone marrow transplantation (BMT), which replaces a patient’s cancer-producing hematopoietic stem cells with ones that produce healthy cells. But even though it’s meant to conclude a patient’s cancer care, even BMT is not a guaranteed cure: 40–50 percent of patients who receive a transplant still relapse (1).
Patients who undergo BMT do not typically receive any additional therapy to prevent relapse. If a patient’s body does not accept the graft and the transplant fails, they will likely also respond poorly to any alternative treatment. However, using more sensitive methods to detect relapse earlier – even before it appears using standard clinical measures – might provide patients with more effective options with respect to chemotherapies and targeted agents.
Read the full article now
Log in or register to read this article in full and gain access to The Pathologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Pathologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.